BSX vs SYK
Boston Scientific and Stryker Corporation, both Healthcare
Stryker Corporation is the larger company at $120B against $67B. On trailing earnings BSX is the cheaper of the two at a P/E of 17.3 against 28.7, a gap that is only a bargain if the two are growing at similar rates. Over the past year SYK returned -26% against -56% for BSX. The RyuScore puts SYK ahead, 66 against 65 out of 100.
| Figure | BSX | SYK |
|---|---|---|
| Last close | $42.74 | $277 |
| Market cap | $67B | $120B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 17.3 | 28.7 |
| 1-year return | -56% | -26% |
| 5-year return | -3.3% | +7.6% |
| RyuScoresector-relative, 1–10 | 65/100 | 66/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Boston Scientific
Revenue of $5.4B in Q2 2026, net income $905M. Its largest reported line is Electrophysiology EP, 18% of the disclosed total.
Stryker Corporation
Revenue of $6.6B in Q2 2026, net income $1.3B. Its largest reported line is Traumaand Extremities, 16% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.